Laura Joszt

Phase 2 data for DD01 and pemvidutide show liver-directed MASH benefits beyond weight loss, with strong tolerability heading into phase 3.

Meena Bansal, MD, discusses the evolving MASH pipeline and why precision phenotyping, biomarkers, and cardiovascular outcomes data remain critical gaps.

Low risk stratification rates are fueling a looming MASH cost crisis, but earlier treatment access could bend the curve, said Zobair M. Younossi, MD.

Re-engagement rates for patients with hepatitis B lost to follow-up range from 2% to 100% globally, with proximity to patients driving the best outcomes.

Elliot Tapper, MD, explains how digital health, precise screening, and direct hepatology care can treat alcohol-associated liver disease and mental health.

Week 96 SOLSTICE data show tobevibart plus elebsiran deepens durable hepatitis D virus (HDV) and HBsAg suppression, beating monotherapy.

A newly approved inhaled insulin expands treatment options for kids with diabetes, offering an alternative to daily injections and pump systems.

Resmetirom boosts MASH cardiovascular protection, lowering LDL cholesterol and Lp(a) even on statins, and pushes routine Lp(a) testing.

DELTA 2 data show topical delgocitinib for chronic hand eczema delivers minimal systemic absorption even under maximal-use conditions.

Pulmonary rehabilitation boosts respiratory strength, the 6-minute walking test, and quality of life in children despite unchanged spirometry.